ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Vitamin D supplements, sleep could help manage pain

Safflower: An Economically Important Herb That Can Benefit Humans and Animals Alike

Bacopa: The Herb That May Increase Your Brain Power

Lilac Oil: More Than Just for Fragrance

Eat More Yogurt and Avoid Osteoporosis

What Is Bilberry Good For?

Coffee, herbal tea may help prevent liver fibrosis

Crafty Uses for Carrot Seed Oil

Higher omega 3 levels linked to improved brain blood flow

Curcumin, resveratrol, ursolic acid show promise against prostate cancer

 
Print Page
Email Article

Potential Anti-Cancer Agent Being Developed from Anti-Inflammation Drug

  [ 20 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 8, 2004


Source: Cancer Research (journal) COLUMBUS, Ohio – Researchers have used a recently developed anti-inflammatory drug as a starting point to construct a possible new, targeted anti-cancer agent. The new agent works by triggering cancer cells to self-destruct. The agent is now undergoing laboratory testing by the National Cancer Institute’s (NCI) Rapid Access to Intervention Development (RAID) program. The potential new drug was developed by researchers at The Ohio State University College of Pharmacy and the OSU Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Presently, the agent is known as OSU-03012. The study is published in the June 15 issue of the journal Cancer Research. “This new agent works by inhibiting a fundamental signaling point in cancer cells, making it potentially effective in a wide range of cancer types,” says study leader Ching-Shih Chen, professor of pharmacy and a researcher with OSU’s Comprehensive Cancer Center. “We also have evidence that it may sensitize leukemia, and breast and lung cancers to conventional chemotherapy.” The new agent is based on the drug celecoxib, a nonsteroidal anti-inflammatory drug, or NSAID. Like many NSAIDs, celecoxib also reduces the risk of colorectal cancer when taken regularly. Scientists knew from the start that celecoxib helps control inflammation by inhibiting an enzyme known as cyclooxygenase-2 (COX-2). But they couldn’t explain the drug’s modest anti-cancer activity. Past work led by Chen provided the answer. “We found that celecoxib’s ability to cause cell death and to control inflammation were two different pharmacological properties, and that the two properties could be separated,” Chen says. This work was published in the Journal of the National Cancer Institute. Chen and his colleagues then showed that celecoxib inhibited a molecule known as Akt. Chen describes Akt as an important molecular switch that transmits information from the cell surface down into the cell to interact with a variety of target molecules. He and colleagues further found that the blocking of Akt by celecoxib in cancer cells triggered programmed cell death, a process also known as apoptosis. For this study, Chen and his colleagues used molecular-modeling methods and computational chemistry to alter celecoxib’s basic molecular structure in ways calculated to maximize its Akt-blocking and cell-death inducing activities. This work generated a series of derivative molecules, all of which were far different in structure from celecoxib. Two of these proved to be 30 to 50 times more potent than celecoxib in inducing programmed cell death in cancer cells growing in the laboratory tests. One of the derivatives, OSU 03012, is now undergoing toxicological and pharmacological testing by the NCI’s RAID program. Data from these tests will help move the agent forward into human testing in a phase I clinical trial, probably within one to two years. Funding from the National Cancer Institute and the Department of Defense Prostate Cancer Research Program supported this research. Source: EurekAlert.org (this is a press release).



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor® Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More
Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing
Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map